Cargando…
In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening
Variability in patient response to anti-cancer drugs is currently addressed by relating genetic mutations to chemotherapy through precision medicine. However, practical benefits of precision medicine to therapy design are less clear. Even after identification of mutations, oncologists are often left...
Autores principales: | Mazzocchi, Andrea R., Rajan, Shiny A. P., Votanopoulos, Konstantinos I., Hall, Adam R., Skardal, Aleksander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811529/ https://www.ncbi.nlm.nih.gov/pubmed/29440675 http://dx.doi.org/10.1038/s41598-018-21200-8 |
Ejemplares similares
-
Immersion Bioprinting of Tumor Organoids in Multi-Well Plates for Increasing Chemotherapy Screening Throughput
por: Maloney, Erin, et al.
Publicado: (2020) -
Application of immune enhanced organoids in modeling personalized Merkel cell carcinoma research
por: Forsythe, Steven D., et al.
Publicado: (2022) -
Detection of lineage-reprogramming efficiency of tumor cells in a 3D-printed liver-on-a-chip model
por: Lu, Zuyan, et al.
Publicado: (2023) -
Cisplatin exhibits superiority over MMC as a perfusion agent in a peritoneal mesothelioma patient specific organoid HIPEC platform
por: Forsythe, Steven D., et al.
Publicado: (2023) -
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations
por: Enomoto, Laura M, et al.
Publicado: (2019)